New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 114.3mg equivalent to 100 mg atomoxetine free base - capsule - 100 mg - active: atomoxetine hydrochloride 114.3mg equivalent to 100 mg atomoxetine free base excipient: dimeticone gelatin   iron oxide red   iron oxide yellow   pregelatinised maize starch sodium laurilsulfate   tekprint black sw-9008   tekprint black sw-9010   titanium dioxide   - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 11.43mg equivalent to 10 mg atomoxetine free base - capsule - 10 mg - active: atomoxetine hydrochloride 11.43mg equivalent to 10 mg atomoxetine free base excipient: dimeticone gelatin pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 114mg equivalent to atomoxetine 100 mg - capsule - 100 mg - active: atomoxetine hydrochloride 114mg equivalent to atomoxetine 100 mg excipient: gelatin   iron oxide red   iron oxide yellow   starch tekprint black sw-9008 tekprint black sw-9009 titanium dioxide   water   - indicated for the treatment of attention deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 20.57mg equivalent to 18 mg atomoxetine free base - capsule - 18 mg - active: atomoxetine hydrochloride 20.57mg equivalent to 18 mg atomoxetine free base excipient: dimeticone gelatin iron oxide yellow pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 28.57mg equivalent to 25 mg atomoxetine free base - capsule - 25 mg - active: atomoxetine hydrochloride 28.57mg equivalent to 25 mg atomoxetine free base excipient: dimeticone gelatin indigo carmine pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 45.71mg equivalent to 40 mg atomoxetine free base - capsule - 40 mg - active: atomoxetine hydrochloride 45.71mg equivalent to 40 mg atomoxetine free base excipient: dimeticone gelatin indigo carmine pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 5.71mg equivalent to 5 mg atomoxetine free base - capsule - 5 mg - active: atomoxetine hydrochloride 5.71mg equivalent to 5 mg atomoxetine free base excipient: dimeticone gelatin iron oxide yellow pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 68.56mg equivalent to 60 mg atomoxetine free base - capsule - 60 mg - active: atomoxetine hydrochloride 68.56mg equivalent to 60 mg atomoxetine free base excipient: dimeticone gelatin indigo carmine iron oxide yellow pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 91.42mg equivalent to 80 mg atomoxetine free base - capsule - 80 mg - active: atomoxetine hydrochloride 91.42mg equivalent to 80 mg atomoxetine free base excipient: dimeticone gelatin   iron oxide red iron oxide yellow pregelatinised maize starch sodium laurilsulfate   tekprint black sw-9008   tekprint black sw-9010   titanium dioxide   - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 114.3 mg (equivalent: atomoxetine, qty 114.3 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.